Q2 sales rise 18%; first-half revenue rises 23% but profit slips

Revenue Growth 20pctResults View source PDF Explain this filing

SURAKSHA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.7%Reaction day

₹317.65

prior close

₹315.05

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%-1.5% vs market

Healthcare Service Provider peers, median of 22sector-0.5%-1.2% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.2 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-1.1

15m

-1.4

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.7-0.3-1.5-0.5-1.2

Next day

-2.2+0.7-2.9+0.4-2.6

-2.2+0.6-2.8+2.1-4.4

-2.4+0.5-2.9+2.0-4.4

-4.9+1.1-6.0+2.3-7.2

-4.9+0.3-5.2-0.5-4.4

-5.3-0.2-5.0+0.4-5.7

15d

-11.3-2.2-9.0-1.1-10.2

-12.2-4.9-7.2-3.8-8.4

-11.9-7.5-4.4-6.0-5.9

-10.3-4.8-5.5-10.2-0.1

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 22Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board approved Suraksha Diagnostic's unaudited group results for September 2025. Q2 revenue was Rs 78.78 crore versus Rs 66.75 crore, up about 18%. First-half revenue rose about 23% to Rs 156.37 crore from Rs 127.49 crore. Q2 profit after tax fell to Rs 8.83 crore from Rs 10.16 crore, while first-half profit was nearly flat at Rs 18.00 crore versus Rs 17.82 crore. The auditor's review found no material problems.

Likely market impact

Higher sales are positive, but flat first-half profit and lower Q2 profit may limit near-term investor enthusiasm and keep the stock outlook mixed.